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Abstract
A number of different interferon-c ELISpot protocols are in use in laboratories studying antigen-specific immune responses.
It is therefore unclear how results from different assays compare, and what factors most significantly influence assay
outcome. One such difference is that some laboratories use a short in vitro stimulation period of cells before they are
transferred to the ELISpot plate; this is commonly done in the case of frozen cells, in order to enhance assay sensitivity.
Other differences that may be significant include antibody coating of plates, the use of media with or without serum, the
serum source and the number of cells added to the wells. The aim of this paper was to identify which components of the
different ELISpot protocols influenced assay sensitivity and inter-laboratory variation. Four laboratories provided protocols
for quantifying numbers of interferon-c spot forming cells in human peripheral blood mononuclear cells stimulated with
Mycobacterium tuberculosis derived antigens. The differences in the protocols were compared directly. We found that
several sources of variation in assay protocols can be eliminated, for example by avoiding serum supplementation and using
AIM-V serum free medium. In addition, the number of cells added to ELISpot wells should also be standardised. Importantly,
delays in peripheral blood mononuclear cell processing before stimulation had a marked effect on the number of detectable
spot forming cells; processing delay thus should be minimised as well as standardised. Finally, a pre-stimulation culture
period improved the sensitivity of the assay, however this effect may be both antigen and donor dependent. In conclusion,
small differences in ELISpot protocols in routine use can affect the results obtained and care should be given to conditions
selected for use in a given study. A pre-stimulation step may improve the sensitivity of the assay, particularly when cells
have been previously frozen.
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Introduction
In the absence of any reliable surrogate markers of protection
against tuberculosis (TB) the monitoring of vaccine-induced
immunity using an effective assay for immune markers is
considered the best selection criterion for moving a new vaccine
candidate forward from Phase 1 and IIa safety and immunoge-
nicity studies through into Phase IIb and Phase 3 efficacy testing.
Markers associated with protection against disease have not yet
been identified, although multiple efforts are ongoing in biomarker
identification and validation [1–3]. The production of interferon-c
(IFN-c), a Th1 cytokine, is frequently measured as an indicator of
immune activity against TB. Although its presence does not
directly imply protection against development of disease, studies
have revealed it to be at least an important component of a
protective immune phenotype [4–7]. The ELISpot assay is an
effective tool to enumerate the number of cells producing IFN-c in
response to a whole series of antigens, including peptides, peptide
pools, proteins and crude bacterial extracts. Tailor-made selection
of antigens can be made, which for vaccine trials will include
specific vaccine components as well as positive and negative
controls. In addition, the ELISpot assay has proven particularly
sensitive in the detection of low-level responses (i.e. memory T-
cells) when compared to other assays [8,9]. The great advantages
of ELISpot are the lack of assay-specific equipment essential for
assay performance, especially when considering developing
countries as important and necessary trial sites for Phase II and
III evaluation, its relative high-throughput performance and its
potential robustness.
Although ELISpot assays will yield potentially very important
data, results may be influenced by variations in the protocol or
even by execution of the same protocol by different laboratory
members [10]. Especially for monitoring of immune responses
where longitudinal follow up of individual patients or volunteers is
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desirable, it is extremely important to have comparable results in
all assays. Monitoring immunity by ELISpot becomes even more
complicated when executed at different study sites between which
data will have to be compared. Depending on the exact study set
up and research questions, samples can be assayed in real-time,
implicating assay variation between follow up time points of each
single volunteer, or all longitudinal samples from a volunteer can
be analysed in a single assay to minimize inter-assay variation and
theoretically increase assay sensitivity. Both strategies have their
own advantages and disadvantages, the most significant being
freezing and thawing of PBMCs in the case of batch analysis.
Fresh and frozen cells may need different protocols to yield
optimal ELISpot results. The addition of a pre-incubation step to
improve assay sensitivity for frozen materials might resolve the
problem of decreased signals, but side-by-side comparisons are
lacking.
In this paper we analysed multiple factors that are of potential
significance for ELISpot performance and identified those that will
need to be harmonized between laboratories if comparisons
between immune responses are to be made. As a starting point we
compared ELISpot protocols used in the authors’ laboratories and
identified the major differences in approach (Table 1). Where
appropriate, these differences may be eradicated for better unity
between studies, or indeed used to identify the best approach for a
given study depending on the specific conditions. Also of note are
protocol steps on which many protocols agree such as the
commercial source of antibody pairs. Although the reasons for this
are not necessarily scientific but may be due to successful
marketing and recommendation by ‘‘word of mouth’’, a strong
case may be made for groups who do not use these reagents to
adopt them.
Materials and Methods
Study Subjects, Venepuncture and PBMC Isolation
The primary goal was to obtain blood from individuals in whom
T-cell responses could reliably be measured by ELISpot. For this
reason, blood samples were obtained from BCG-vaccinated
healthy adult or M. tuberculosis latently infected volunteers from
participant institutes after receipt of written consent and ethical
approval. All laboratories involved have experience in measuring
T-cell responses to mycobacterial antigens such as Mtb PPD in
these subjects. Venous blood was drawn and transferred to a tube
containing 10 units of preservative-free sodium heparin per
millilitre of blood. PBMC were separated from peripheral blood
by density gradient centrifugation and transferred into a separate
tube. In some cases, autologous plasma was also collected at this
stage and stored until required. Viable PBMC were enumerated
by eye using light microscopy and a Neubauer haemocytometer
(Weber). All counts were duplicated for accuracy and non-viable
cells were identified by Trypan Blue (Sigma) exclusion.
Short-Term Cultured ELISpot
The nature of the experiments described here were such that
various protocol points were varied in order to observe the effect of
different approaches. The following are the basic methods for
short-term cultured and ex vivo ELISpot assays. Where conditions
were altered, this is described in the results section and in figure
legends.
One million PBMC were transferred to 5 ml polypropylene
tubes in 500 ml AIM-V (Invitrogen). Antigen was added to
stimulation tubes (with one tube left as a control containing
medium alone). Tubes were incubated overnight at 37uC (5%
CO2) in a humidified incubator. At the same time, ELISpot plates
were coated with anti-IFNc capture antibody (Mabtech Ab 1-
DIK). PVDF-backed ELISpot plates (MAIPS4510, Millipore)
were pre-wet with 25 ml of 70% ethanol for no more than
2 minutes then washed twice with 200 ml per well sterile PBS
(pH 7.4). Fifty microlitres of capture antibody was added to each
well at a concentration of 15 mg/ml in PBS and plates were
incubated overnight at 4uC. The following day, plates were
washed with 200 ml per well of PBS five times and blocked with
200 ml per well of RPMI 1640 (Cambrex) with 10% foetal calf
serum (HyClone, Perbio) for at least 1 hour at 37uC. Plates were
then washed again three times with PBS. Overnight antigen-
stimulated and control cells were resuspended by pipetting and 36
125 ml (corresponding to 2.56105 input PBMC in triplicate) were
transferred to ELISpot plates in triplicate. ELISpot plates were
then incubated at 37uC for a further 24–48 hours. After this time,
plates were emptied by flicking and wells were washed five times
with 200 ml of PBS with 0.05% Tween-20 (Sigma). Anti-IFNc–
biotin detection antibody (Mabtech 7-B6-1) was diluted to 1 mg/
Table 1. Major differences (and similarities) in ELISpot protocols submitted by 4 participant laboratories.
PROTOCOL STEP LABORATORY A LABORATORY B LABORATORY C LABORATORY D
Pre-incubation step Yes. Overnight +/2 antigen in polypropylene
tubes
Yes. Overnight +/2 antigen
in 48 well tissue culture
plates
No No
Amount of anti-IFNc coating
antibody used
100ml at 15mg/ml 100ml at 5mg/ml 50ml at 15mg/ml 50ml at 15mg/ml
Number of cells per ELISpot
well (used for test antigens)
2.56105 or 0.6256105 for Ag mixture or
0.316105 for positive control (calculated from
proportion of original culture transferred)
2.56105 (calculated from
proportion of original
culture transferred)
1.06105 3.06105
Time in ELISPOT plates 48 hours 18–24 hours 18–24 hours 18–24 hours
Culture medium used RPMI 1640+10% HI-FCS RPMI 1640+10% pooled
HI- AB human serum
RPMI 1640+5%
autologous plasma
RPMI 1640+10% HI-FCS
ELISpot Plates PVDF-backed (Millipore, MAIPS4510) As for Laboratory A As for Laboratory A As for Laboratory A
Capture Antibody Anti-IFNc (Mabtech 1-D1K) ‘‘ ‘‘ ‘‘
Detection Antibody Biotinylated anti-IFNc (Mabtech 7-B6-1) ‘‘ ‘‘ ‘‘
ELISpot Plate Pre-treatment 70% Ethanol ‘‘ ‘‘ ‘‘
doi:10.1371/journal.pone.0007972.t001
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ml in PBS with 0.5% FCS and 50 ml added to each well. Plates
were then incubated at room temperature for 2 hours. Plates were
washed in PBS/Tween as previously and 50 ml per well of
streptavidin-ALP (Mabtech IFNc ELISpot kit reagent) at a 1/1000
dilution in PBS/FCS was added to each well. Plates were again
incubated at room temperature for 2 hours. After a final wash with
200 ml per well of PBS/Tween63 and PBS alone63, plates were
developed for up to 30 minutes with BCIP/NBTPLUS (Moss Inc.,
Maryland) following the manufacturers instructions. Reactions
were stopped by washing with tap water after which plates were
allowed to dry before spot counting.
Ex Vivo ELISpot Assay
Plates were pre-wet and coated and blocked using the same
procedure as for the cultured ELISpot with minor alterations.
After blocking, PBMC without any prior manipulation following
isolation from peripheral blood were added to wells. Antigen was
added to stimulation wells otherwise cells were left in medium
alone. The final volume was 200 ml per well. Each condition was
tested in at least duplicate. M.tb PPD (Staten Serum Institute) was
used at a final concentration of 10 mg/ml. ELISpot assays were
cultured at 37uC for between 18 and 20 hours. Following
incubation, the plates were washed, probed with detection
antibody and streptavidin-ALP and developed using the AP
Conjugate Substrate Kit (Biorad).
Cryopreservation of PBMC
In some experiments, PBMC were cryopreserved prior to
ELISpot assays. PBMC were resuspended in RPMI 1640 with
20% FCS at 26107 cells per ml and cooled on ice for 30 minutes.
An equal volume of pre-cooled RPMI 1640 with 20% FCS and
20% DMSO (Sigma) was then added dropwise to the cell
suspension. Cells were then distributed into cryovials (Nunc) at 107
(1ml) per tube and cryopreserved at 280uC in Mr. Frosty
containers (Nalgene). Vials were then transferred to liquid nitrogen
after a day and stored for 4 weeks. To thaw, vials were defrosted
quickly in a 37uC water bath and the contents transferred to a
15 ml centrifuge tube (Greiner) containing 2 mls of RPMI 1640
with 50% FCS. RPMI 1640 without FCS was then added to a
volume of 14 ml and tubes centrifuged at 439g for 7 minutes.
Pellets were resuspended in 1 ml AIM-V medium and cells
counted. Recovered PBMC were enumerated by eye as described
above. Viable cell recovery was routinely between 70–90%.
Results and Discussion
ELISpot Plate Preparation
The protocol steps used to prepare ELISpot plates for the
addition of cells and antigen were found to vary between groups,
e.g. type of plate used, employment of an ethanol pre-wash, wash
and coating buffers used, coating antibody concentration and
blocking buffer formulation. As manufacturers develop newer
plates better suited to applications such as the ELISpot assay (such
as using white plastic instead of clear plastic or different membrane
compositions), such products are adopted by some groups whereas
others are satisfied with the performance of earlier products. Also,
one laboratory may have achieved acceptable results after washing
wells in culture medium whereas others have been similarly happy
with phosphate buffered saline (PBS) as a washing solution. It was
thought that variables such as these might affect spot quality (i.e.
size and density) and so lead to differences in spot number when
software settings are such that they discriminate between a large
fuzzy spot and a small well defined spot. When some of these
conditions were compared in side-by-side assays, they had little
effect on the number of spots counted (data not shown). We
concluded that, in the interests of harmonisation, it would be
feasible for groups to agree on steps such as these (suggested
conditions for these steps are given in example ELISpot protocols
S1 and S2 presented as supplementary material).
Sample Preparation
Processing delays. Immunomonitoring of humans may be
carried out in such a way that, in some instances, blood is taken
on-site and processing can start immediately once the sample is
collected, whilst in other settings, samples have to be transported
some distance between the place of venepuncture and the
laboratory. It has been reported by others that losses in
sensitivity of short term assays (18 hrs) for T-cell function can
result from delaying the processing of blood samples and the
commencement of assay cultures [11,12]. In agreement with this,
we also found that the number of spot forming cells detected by
ELISpot was significantly less when sample processing was delayed
for four hours (whole blood, stored at room temperature)
compared to immediately processed aliquots (Figure 1).
The time taken to process blood samples may be difficult to
synchronize between study sites as the specific field conditions will
inevitably vary. It is however apparent that this important factor
will impact upon data collected using the ELISpot assay and must
be considered when analyzing results. One approach would be to
decide on a length of time to delay sample processing at all sites
based on the site where the longest delay is inevitable.
Assay Procedure
Media and sera. Protocol variations in steps involving the
culture of PBMC with antigen in ELISpot assays were suspected to
have the greatest capacity to alter the assay outcome. It was
apparent from a comparison of protocols used in our laboratories
and those of others that culture medium composition represented
a variable in different laboratories. Examples of the use of media
supplemented with foetal calf serum, human pooled AB serum and
Figure 1. Delays in blood sample processing result in losses of
ELISpot assay sensitivity. Aliquots were taken from whole blood
samples of BCG-vaccinated adults (n = 8) and either processed
immediately or delayed for 4 hours at room temperature before PBMC
were prepared by centrifugation over Ficoll. PBMC were suspended in
AIM-V serum free medium and stimulated with M.tb PPD (10 mg/ml) in
ELISpot plates (2.56105 PBMC per well) for 18 hours prior to spot
development and counting. Plates were developed according to kit
manufacturers instructions (Mabtech). Results are SFC per million PBMC
in antigen-stimulated samples minus that measured in medium only
samples. Statistical analysis is by paired t-test.
doi:10.1371/journal.pone.0007972.g001
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autologous sera were found as well as the use of serum-free
medium alternatives [13].
As the use of serum could introduce variability over time as it
becomes necessary to introduce fresh serum batches, we were
interested in the possibility of substituting serum-supplemented
medium for a serum free alternative without the loss of assay
sensitivity. We found that the measurable ELISpot response to
PPD in BCG vaccinated individuals in serum free AIM-V medium
was comparable to responses measured with either autologous or
pooled AB human serum and that the lack of serum did not result
in measured responses that were significantly any less than those
measured in assays where serum was used (Figure 2). The median
response to PPD in AIM-V medium was 203 spot-forming cells
per million PBMC and the interquartile range 97–373. The
corresponding data for un-stimulated controls was 10 (6–15).
These data indicate that AIM-V is capable of detecting both high
and low responses as well as ensuring a high signal to background
ratio (20:1 in this case). Thus, substitution of serum containing
media with AIM-V synthetic medium would eliminate a potential
source of variation. As the avoidance of serum supplementation is
an easily achievable way to reduce inter-assay variation between
laboratories as well as in a single laboratory over time for
longitudinal studies, the adoption of a serum free medium such as
AIM-V would be an effective way to ensure assay uniformity.
Cell numbers used. One of the most relevant considerations
when deciding how many cells to add to ELISpot wells may be the
expected magnitude of the response to be measured. Predicting
this magnitude should help to avoid the outcome of uninformative
‘‘blacked out’’ wells (containing too many spots to count reliably)
for strong responses or, conversely, too few spots to count when
responses are weak. The nature of the immune response being
tested and the recall antigen used to monitor responses will often
affect this decision. If, for example, a potent vaccine regime (e.g. a
prime-boost approach) is used and/or if the recall stimulus is
particularly immunogenic, the number of spots detectable will be
greater. In these circumstances, fewer cells may be added to
ELISpot wells in order to avoid black out. The reverse is true
when the vaccine or stimulus is weaker. More cells may be
required to achieve enough spot-forming cells to exceed the
threshold of detection in a given well.
It might be assumed that for one set of assay conditions, the
number of spots counted after varying the number of cells added
to a well would be normalized (by calculating the number of spots
per million PBMC) to give the same result. However, we found
that for a given donor and stimulus, altering the number of cells in
a well does not equate linearly to the same overall response when
spot counts are converted to spot forming cells per million PBMC.
This was demonstrated for both PPD in the standard ex vivo
ELISpot assay (Figure 3A) and for the protein antigen HBHA in
an ELISpot assay following a pre-incubation step with antigen
(Figure 3B). In other words, there is not necessarily a linear
relationship between the number of cells added to a well and the
number of spots produced in that well. It is likely not possible to
add equal cell numbers for stimulants as disparate as the positive
control anti-CD3 and (protein) antigens such as HBHA [14–16]
and expect readable, useful spot counts for both. Hence, when
responses to particular stimuli such as PPD or anti-CD3 are to be
measured at different sites, efforts should be made to ensure that
the same numbers of cells are indeed being added to wells for a
given stimulus and that these numbers relate to the expected
magnitude of response and hence the number of spots per well.
Precision in the counting of cells and of pipetting technique are
essential considerations in order to achieve the desired number of
cells per well. Repeat counts (manual or automated) that are
averaged and properly calibrated pipettes are therefore vital.
Given that, as yet undefined mechanisms result in measured
responses that are not proportional when different input cell
numbers are used, the approach outlined above should allow
meaningful comparisons between responses to a given antigen.
Assuming the number of stimuli to be tested is not large it may be
necessary to include separate medium control wells for each cell
number used as background spot counts may also be affected.
Ex vivo ELISpot assay or short-term cultured ELISpot
assay. If the definition of an ELISpot assay is restricted to the
period during which cells are cultured with stimulant in a well
coated with capture antibody and the subsequent processing of
that plate with detection antibody and colour development
reagents, a major difference in approach we encountered was
the inclusion of a PBMC stimulation step prior to the ELISpot
assay; an approach that is termed a short-term cultured (STC)
ELISpot assay. This pre-stimulation step was carried out either in
multi-well tissue culture plates or in polypropylene centrifuge tubes
and comprised the culture of cells with stimulant for a defined
period, prior to their addition to coated ELISpot wells. The
rationale for this approach is to increase the assay’s sensitivity
when study conditions exist in which responses may be less
marked, as well as to decrease the background due to the presence
of dead cells (in the case of frozen samples only). These conditions
may relate to the immune response to be measured or the recall
antigen used as discussed, or particularly when longitudinal studies
require that samples from different time points are frozen and
processed later in batches, to minimize variation in test responses
that could well be caused by temporal inter-assay variability. In the
current study we attempted to determine whether the STC
ELISpot assay did indeed improve the sensitivity of the assay
above that of a direct, ‘‘ex vivo’’ assay and whether this was
indicated by greater spot counts for otherwise identically treated
Figure 2. A comparison of the effects of different culture media
used in ELISpot assays. Spot numbers in un-stimulated and in M.tb
PPD stimulated ex vivo ELISpot assays were determined following the
use of different culture media (AIM-V serum-free medium; RPMI 1640
medium supplemented with heat inactivated human pooled AB serum
(RPMI AB) or RPMI 1640 medium supplemented with autologous serum
(RPMI AUT). Results are SFC per million PBMC in M.tb PPD-stimulated
samples minus that measured in medium only samples. Box and
whisker plots show the median, upper and lower quartiles and range of
the response (n = 8). Statistical analysis is by paired t-tests.
doi:10.1371/journal.pone.0007972.g002
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samples. When this comparison was carried out at the four sites,
we observed a mixed outcome. When responses to M.tb PPD were
investigated, although there was considerable variation between
laboratories, as represented by the data spread within each group,
the combined results from all four laboratories indicated that a
pre-stimulation did increase the number of spot forming cells
detected over those observed in parallel ex vivo assays, and that this
was true for both fresh and cryopreserved samples (Figure 4).
Results were less consistent when responses to all antigens tested
(including PPD, protein and peptide antigens) were considered.
When analysis was restricted to either protein antigens expressed
in BCG (Ag85A, Ag85B) and to samples from donors known to be
BCG vaccinated but not TB exposed, or to a latency protein
antigen tested in latently infected subjects (HBHA), the pre-
stimulation step again increased the number of spot forming cells
detected (data not shown). The variation in responses observed by
each laboratory may be due to the differing backgrounds of
volunteer donors; e.g. age, BCG vaccine and travel history or
possible exposure to TB. Despite this, it seems that for studies in
which immune responses may be less marked the inclusion of a
pre-stimulation step might be considered in order to improve the
sensitivity of the ELISpot assay.
Plate Reading
Even in situations where ELISpot assay conditions have been
harmonized across sites as completely as possible, comparable
results will depend upon the accurate enumeration of spots in each
well. As the ELISpot technique has been adopted by different
laboratories over time, various types of spot counting instruments
and versions of the accompanying software have been obtained by
each. Without a standardised approach to instrument set-up and
with spot counting parameters being set by individual users in each
laboratory one might expect a degree of variability when different
laboratories are given the same ELISpot plate to count.
Two ELISpot plates containing 30 separate assays were
circulated between the four laboratories involved in this study.
The details of each of the 30 assays (10 separate conditions tested
in triplicate) are described in Table 2. Each laboratory counted
these according to their own settings for the counting of IFN-c
ELISpot plates using automated readers (Figure 5A). A degree of
variability was indeed observed. Interestingly, 2/4 laboratories
obtained similar counts that were appreciably different to those
obtained by the remaining 2 laboratories, between which there
was again a good degree of agreement. The degree of variability
between results produced by the four laboratories (represented as
the standard deviation from the mean) increased as the mean
response in a particular assay increased (Figure 5B). However,
Figure 4. Comparison of ‘‘ex vivo’’ and short-term cultured
‘‘pre-stimulation’’ ELISpot techniques. M.tb PPD-stimulated re-
sponses were determined using either the ex vivo approach on fresh
(n = 14) and cryopreserved (n = 10) or using the pre-stimulation (STC)
approach on fresh (n = 12) or cryopreserved (n = 14) PBMC samples.
Results are combined data from donors tested in 4 laboratories.
Unreadable (blacked out) ELISpot readings were allocated a count of
1000 SFC/million PBMC. Box and whisker plots show the median, upper
and lower quartiles and range of the response. Statistical analysis is by
paired t-tests.
doi:10.1371/journal.pone.0007972.g004
Figure 3. The effect of input PBMC number per well on ELISpot
assay performance. Spot numbers in (A) M.tb PPD stimulated, ex vivo
ELISpot assays (n = 8) or (B) HBHA-stimulated, short-term cultured
ELISpot assays (n = 6) were determined following the addition of
varying PBMC numbers per well. All results were obtained after the
subtraction of background spots (measured in unstimulated wells). Box
and whisker plots show the median, upper and lower quartiles and
range of the response. Data shown are representative of similar
experiments carried out in 3 of the 4 laboratories involved. Statistical
analysis is by paired t-tests.
doi:10.1371/journal.pone.0007972.g003
Factors Influencing ELISpot
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Figure 5C shows that when considered as a percentage of the
mean response, the standard deviation remained consistent over
the range of response magnitudes (Figure 5C). Together, these two
findings suggest that there is less variability between counts
produced by different laboratories when responses are lower
overall. The implication of this is that laboratories are more likely
to agree when responses are close to the borderline between
positive and negative resulting in a similar ranking of responses.
Although automated counting is the most easily employed
method to achieve consistency, spot counting hardware and
software will often vary between laboratories. As seen here, the
counting of two plates can vary between sites which have different
readers and software. In the absence of matching equipment, an
approach would be to circulate a batch of ELISpot plates around
participating sites and allow the adjustment of machines and
software settings in order that all counters read the same number
of spots for those plates. This process would be facilitated by prior
agreement as to the characteristics of spots that are to be counted
as opposed to those that may be considered background spots and
ignored. The important characteristics to consider are usually spot
size, spot density, spot shape and the ‘‘fuzziness’’ of a spot’s edges.
Alternatively, all plates may be sent (blinded) to and read by one
centre on a single instrument by one operator. The easiest
approach may simply to ensure that all sites involved in a study
have matching hardware, software and instrument settings before
commencement.
Analysis
Depending on how results are to be presented, it may be
necessary to determine parameters for analysis such as a cut off
point between positive and negative ELISpot assay results. The
most common approach is the requirement that for a positive
response to a given antigen, the average number of spots counted
in the test wells is at least double that counted in the control wells
(usually cells cultured in medium alone) and also that there is a
difference of at least 5 spots between control and test wells. This is
the criterion utilised when the ELISpot assay is employed
commercially to identify latent TB and has a history of use in
studies where ELISpot has been used [17–20].
Conclusion
The ELISpot assay is a widely used method for detecting T-cell
responses to antigens of interest, but variations in protocol can
alter the results obtained. Such differences jeopardize comparisons
made, for example between different vaccine candidates tested in
different trials with alternative assay procedures. The recommen-
dations presented here provide a means by which all sites
participating in a trial or comparative trials of novel TB vaccines,
or indeed any multi-centre study where immunological monitoring
by ELISpot assay is desirable, can ensure that variations due to
assay procedure are kept to a minimum. We see our findings as
indicators of where differing ELISpot protocols might be altered to
make them more comparable. Although the implications of some
of this study’s comparisons for complete assay harmonisation
within the field are limited by sample sizes of 8 or less (e.g. serum
usage) we believe that these results provide a useful guide as to
where more comprehensive harmonisation might begin. Similarly,
we acknowledge that the list of possible factors that contribute to
variations in the sensitivity and specificity of the ELISpot assay is
extensive and those covered here represent only a few. We believe
however that the impact of those mentioned is potentially great
and that these are important factors to address.
To summarise, although unlikely to markedly affect assay
performance, plate preparation, washing and blocking procedures
should be consistent. We recommend the use of PBS for washing,
antibody dilution and blocking (when supplemented with serum)
for the simple reasons that it is easiest (and cheapest) reagent on
which groups can agree and it has been used successfully for these
purposes in the past. In order to minimize assay variations, a
serum free medium such as AIM-V is recommended for the cell
culture step and for a given study and recall antigen, the number
of cells added to wells should be the same at all sites. Every effort
should be made to ensure that samples undergo similar treatment
at all sites including the time taken from venepuncture to PBMC
preparation, dilution in medium and addition to ELISpot plates.
When employed, cryopreservation and thawing procedures should
be consistent, agreed beforehand and harmonized on issues of
freezing media, batches of foetal calf serum and dimethyl sulfoxide
and use of NalgeneH Mr. Frosty containers.
The ex vivo ELISpot assay (see Protocol S1) is recommended for
use on freshly prepared PBMC and when a strong T-cell response
is predicted, e.g. in vaccine trials for prime-boost regimes or novel
live vaccines. The short-term cultured ELISpot assay (see Protocol
S2) is recommended for use when sample arrival is unpredictable
or when weaker T-cell responses are expected, e.g. when PBMC
samples have been cryopreserved and banked for batch
processing.
Where possible, the same spot counting procedure, equipment
and software (including settings) should be used. In addition (and
especially when equipment or software differs) reference plates
should be circulated between sites and equipment should be
configured in such a way that all sites obtain the same readings
from these plates.
ELISpot harmonisation is an important consideration before
performing large scale immune-monitoring studies such as clinical
trials of novel vaccines. We present here some considerations and
recommendations that should facilitate the implementation of
strategies for such harmonisation.
Supporting Information
Protocol S1 Recommended protocol for carrying out the ex vivo
ELISpot assay based on findings in paper
Found at: doi:10.1371/journal.pone.0007972.s001 (0.05 MB
DOC)
Protocol S2 Recommended protocol for carrying out the short-
term cultured (STC) ELISpot assay based on findings in paper
Table 2. Description of assays represented in Figure 5 for
which each laboratory provided separate spot counts.
ASSAY CONDITIONS ASSAY NUMBER
Human AB serum; Coating mAb – 50ml 1, 11, 24
Human AB serum; Coating mAb – 100ml 3, 15, 21
Autologous serum; Coating mAb – 50ml 2, 16, 27
Autologous serum; Coating mAb – 100ml 13, 17, 28
AIM-V serum-free medium; Coating mAb – 50ml 5, 14, 25
AIM-V serum-free medium; Coating mAb – 100ml 9, 10, 22
PPD conc. 5 mg/ml; sample handling – no delay 6, 8, 26
PPD conc. 10 mg/ml; sample handling – no delay 4, 7, 23
PPD conc. 5 mg/ml; sample handling – delayed 4 hr 18, 20, 30
PPD conc. 10 mg/ml; sample handling – delayed 4hr 12, 19, 29
doi:10.1371/journal.pone.0007972.t002
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Figure 5. ELISpot reference plate counts obtained independently from four laboratories. Results show spot counts per well for each of 30
separate ‘‘assays’’ (i.e. results from donor PBMC stimulated independently with conditions varied) (A); the standard deviation of responses between
laboratories as a function of the average between laboratories response (B) and the standard deviation as a proportion of the between laboratories
mean response (C).
doi:10.1371/journal.pone.0007972.g005
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Found at: doi:10.1371/journal.pone.0007972.s002 (0.05 MB
DOC)
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